Seclidemstat

Seclidemstat
Clinical data
Other names	SP-2577
Drug class	LSD1 inhibitor
Identifiers
	IUPAC name N-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide;
CAS Number	1423715-37-0;
PubChem CID	135565033;
ChemSpider	64853793;
UNII	TYH386V3WJ;
KEGG	D12577;
ChEMBL	ChEMBL4297641;
Chemical and physical data
Formula	C20H23ClN4O4S
Molar mass	450.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C/C(=N\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)/C3=C(C=CC(=C3)Cl)O;
	InChI InChI=InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)/b22-14+; Key:MVSQDUZRRVBYLA-HYARGMPZSA-N;

Seclidemstat is an investigational new drug that is being evaluated for the treatment of cancer.^[1] It is a small-molecule inhibitor of lysine-specific demethylase 1 (LSD1, KDM1A).^[2]

References

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.